ALCAM and malignant colon neoplasm: Another study, using a cohort of patients with colon cancer (n = 234) who received 5-FU (fluorouracil)-based chemotherapies after surgery, indicated that ALCAM polymorphisms (G > A) alone or with polymorphisms of LGR5 (T > C) and CD44 (C > T) and ALDH1A1 (G > C) are important factors in predicting extended time to recurrence and, in particular a combination of LGR5, CD44 and ALDH1A1 (although only LGR5 polymorphisms is a factor in predicting resistance to 5-FU-based therapies), not ALCAM [102].